Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 41 articles: HTML format

Single Articles

April 2024
1. BRUDON A, Legendre M, Mageau A, Bermudez J, et al
   High risk of lung cancer in surfactant-related gene variant carriers.
   Eur Respir J. 2024 Apr 4:2301809. doi: 10.1183/13993003.01809-2023.
   PubMed     Abstract available
   
   
   March 2024
2. YOON HY, Kim SY, Song JW
   Association Between High Levels of Nitrogen Dioxide and Increased Cumulative Incidence of Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis.
   Eur Respir J. 2024 Mar 7:2301181. doi: 10.1183/13993003.01181-2023.
   PubMed     Abstract available
   
   
   February 2024
3. 
   "ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer." E.L. O'Dowd, I. Tietzova, E. Bartlett, et al. Eur Respir J 2023; 62: 2300533.
   Eur Respir J. 2024;63:2350533.
   PubMed    
   
   
   January 2024
4. OBACZ J, Valer JA, Nibhani R, Adams TS, et al
   Single-cell transcriptomic analysis of human pleura reveals stromal heterogeneity and informs in vitro models of mesothelioma.
   Eur Respir J. 2024;63:2300143.
   PubMed     Abstract available
   
   
   October 2023
5. O'DOWD EL, Tietzova I, Bartlett E, Devaraj A, et al
   ERS/ESTS/ESTRO/ESR/ESTI/EFOMP statement on management of incidental findings from low dose CT screening for lung cancer.
   Eur Respir J. 2023 Oct 6:2300533. doi: 10.1183/13993003.00533-2023.
   PubMed     Abstract available
   
   
   May 2023
6. BALDWIN D, O'Dowd E, Tietzova I, Kerpel-Fronius A, et al
   Developing a Pan-European Technical Standard for a Comprehensive High-quality Lung Cancer CT Screening Program. An ERS Technical Standard.
   Eur Respir J. 2023 May 18:2300128. doi: 10.1183/13993003.00128-2023.
   PubMed     Abstract available
   
   
   March 2023
7. DESBORDES P, De Vos M, Maes J, de Jongh F, et al
   Implications of the new ERS/ATS standards on the interpretation of lung function tests.
   Eur Respir J. 2023;61:2202348.
   PubMed    
   
   
   February 2023
8. RAMI-PORTA R, Fong KM
   Stage IV lung cancer: the relevance of tumour profile for the construction of prognostic groups.
   Eur Respir J. 2023;61:2202094.
   PubMed    
   
   
   
9. GOZAL D, Kolb M
   Nintedanib in chILD: a small step, yes... but at least a step forward in a marathon!
   Eur Respir J. 2023;61:2201797.
   PubMed    
   
   
   January 2023
10. WANG XF, Li QY
    Optimised surveillance of minor to moderate bronchial dysplasia in a risky population: more precision strategies needed.
    Eur Respir J. 2023;61:2202264.
    PubMed    
    
    
    December 2022
11. EYMIN B
    Inspiratory hyperoxia: a new way to prevent metastasis through metabolism reprogramming in non-small cell lung cancer.
    Eur Respir J. 2022;60:2201357.
    PubMed    
    
    
    
12. CRESTANI B, Kolb M
    Lung cancer in pulmonary fibrosis: no room for nihilism!
    Eur Respir J. 2022;60:2201946.
    PubMed    
    
    
    
13. ZHANG L, Lu FY, Huang SG, Li QY, et al
    Ventilation and tumour spread: still a pending matter.
    Eur Respir J. 2022;60:2201674.
    PubMed    
    
    
    
14. LOPEZ-ALONSO I, Fueyo A, Albaiceta GM
    Reply to: Ventilation and tumour spread: still a pending matter.
    Eur Respir J. 2022;60:2201826.
    PubMed    
    
    
    November 2022
15. BLUM TG, Morgan RL, Durieux V, Chorostowska-Wynimko J, et al
    European Respiratory Society Guideline on various aspects of quality in lung cancer care.
    Eur Respir J. 2022 Nov 17. pii: 13993003.03201-2021.
    PubMed     Abstract available
    
    
    
16. MAGENHEIM J, Rokach A, Peretz A, Loyfer N, et al
    Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    September 2022
17. METZENMACHER M, Griesinger F, Hummel HD, Elender C, et al
    Prognostic factors in non-small-cell lung cancer: insights from the German crisp registry.
    Eur Respir J. 2022 Sep 30. pii: 13993003.01336-2022.
    PubMed     Abstract available
    
    
    
18. GUISIER F, Deslee G, Birembaut P, Escarguel B, et al
    Endoscopic follow-up of low-grade precancerous bronchial lesions in high-risk patients: long-term results of the SELEPREBB randomised multicentre trial.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    August 2022
19. STANOJEVIC S, Kaminsky DA, Miller M, Thompson B, et al
    Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
20. NEDER JA
    The new ERS/ATS standards on lung function test interpretation: some extant limitations.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    July 2022
21. TISI S, Dickson JL, Horst C, Quaife SL, et al
    Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry.
    Eur Respir J. 2022 Jul 26. pii: 13993003.00795-2022.
    PubMed     Abstract available
    
    
    
22. CROSBIE PAJ, Gabe R, Simmonds I, Hancock N, et al
    Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00483-2022.
    PubMed     Abstract available
    
    
    
23. KALINKE L, Janes SM
    Two phenotypes that predict prognosis in lung adenocarcinoma.
    Eur Respir J. 2022;60.
    PubMed    
    
    
    
24. LAMORT AS, Kaiser JC, Pepe MAA, Lilis I, et al
    Prognostic phenotypes of early-stage lung adenocarcinoma.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    
25. LOPEZ-ALONSO I, Lopez-Martinez C, Martin-Vicente P, Amado-Rodriguez L, et al
    Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content.
    Eur Respir J. 2022;60.
    PubMed     Abstract available
    
    
    June 2022
26. LIU X, Qin H, Li Z, Lv Y, et al
    Inspiratory hyperoxia suppresses lung cancer metastasis through a MYC/SLC1A5-dependent metabolic pathway.
    Eur Respir J. 2022 Jun 9. pii: 13993003.00062-2022.
    PubMed     Abstract available
    
    
    May 2022
27. OKI M, Saka H, Imabayashi T, Himeji D, et al
    Guide sheath versus non-guide sheath method for endobronchial ultrasound-guided biopsy of peripheral pulmonary lesions: a multicentre randomised trial.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    March 2022
28. OTSUBO K, Kishimoto J, Ando M, Kenmotsu H, et al
    Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial.
    Eur Respir J. 2022 Mar 31. pii: 13993003.00380-2022.
    PubMed     Abstract available
    
    
    
29. SUCCONY L, Gomez-Lopez S, Pennycuick A, Alhendi ASN, et al
    Lrig1 expression identifies airway basal cells with high proliferative capacity and restricts lung squamous cell carcinoma growth.
    Eur Respir J. 2022;59.
    PubMed     Abstract available
    
    
    January 2022
30. SUN TY, Hwang G, Pancirer D, Hornbacker K, et al
    Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour.
    Eur Respir J. 2022;59.
    PubMed    
    
    
    December 2021
31. ZHANG J, Guo JR, Huang ZS, Fu WL, et al
    Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial.
    Eur Respir J. 2021;58.
    PubMed     Abstract available
    
    
    November 2021
32. SOROLLA A, Parisi E, Sorolla MA, Marques M, et al
    Applications of CRISPR technology to lung cancer research.
    Eur Respir J. 2021 Nov 4. pii: 13993003.02610-2021.
    PubMed    
    
    
    October 2021
33. SCHREUDER A, Jacobs C, Lessmann N, Broeders MJ, et al
    Scan-based competing death risk model for reevaluating lung cancer computed tomography screening eligibility.
    Eur Respir J. 2021 Oct 14. pii: 13993003.01613-2021.
    PubMed     Abstract available
    
    
    
34. HENDRIKS LEL, van Meerbeeck J, Cadranel J
    Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?
    Eur Respir J. 2021;58.
    PubMed    
    
    
    
35. ASFAHAN S, Elhence P, Dutt N, Niwas Jalandra R, et al
    Digital-Rapid On-site Examination in Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (DEBUT): a proof of concept study for the application of artificial intelligence in the bronchoscopy suite.
    Eur Respir J. 2021;58.
    PubMed    
    
    
    September 2021
36. HENROT P, Beaufils F, Thumerel M, Eyraud E, et al
    Circulating fibrocytes as a new tool to predict lung cancer progression after surgery?
    Eur Respir J. 2021 Sep 24. pii: 13993003.01221-2021.
    PubMed    
    
    
    July 2021
37. LI G, Zhang X, Liu Y, Zhang J, et al
    Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study.
    Eur Respir J. 2021 Jul 29. pii: 13993003.01399-2021.
    PubMed     Abstract available
    
    
    June 2021
38. CHERNBUMROONG S, Johnson J, Gupta N, Miller S, et al
    Machine learning can predict disease manifestations and outcomes in lymphangioleiomyomatosis.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    April 2021
39. MALDONADO F, Varghese C, Rajagopalan S, Duan F, et al
    Validation of the BRODERS classifier (Benign versus aggRessive nODule Evaluation using Radiomic Stratification), a novel HRCT-based radiomic classifier for indeterminate pulmonary nodules.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    
    March 2021
40. HASANI AM, Matthew B, Goljamali M, Chen YC, et al
    Effect of non-uniform cyst distribution in lymphangioleiomyomatosis on pulmonary function: a cross-sectional study.
    Eur Respir J. 2021;57.
    PubMed    
    
    
    
41. FERNANDES S, Williams G, Williams E, Ehrlich K, et al
    Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies.
    Eur Respir J. 2021;57.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.